doom , doom, its down 2 p today, no news,its the end of the world,and I will continue to hold.

Nobody else seems to be interested, I may be lonely but AMS continues to shine.
71.5 bid today on high volume.I do not like those that forecast market prices in the near future, but my worry is that one of the big medical houses will come along offering the money before the market realises just what this company is worth.
Why should I worry, I seem to be the only one here.

You are not alone, I'm completely with you having held shares for a few months now after a bid for the company was rejected and a higher bid did not materialise but the potential prospects were there for the company to get recognition by the City - perhaps that is beginning to happen now as I cannot see any substantial news at present to send the price on an upward spiral but long may it continue

mogkins

sorry to not to have noticed your comment before today.
I am sure that there are more than we two here but most are very bashful.
with 19 mill share trade over the past few days against an normal 2/300 k per day I am awaiting news. Some old hands are suspecting an agreed bid, I do not know other than we should be seeing an flag soon as the volume trade against the 145 mill issued must call for somebody to admit there holdings have changed.
The house broker kept away as the price jumped last week, now he is on the fringe.
Interesting times, but must stop guessing

This morning we have ourselves a breakout to a new high by the looks of it.



Recent article at proactiveinvestors.com:

Thursday, October 21, 2010

Advanced Medical Solutions sets its sights on the US
by Ian Lyall

WHAT do silver and super-glue have in common?

No idea? Well, the answer is they are the cornerstones of growth for wound-care company Advanced Medical Solutions (LON:AMS).

Silver is the infection retarding agent the company uses in the SilverCel range of dressings, while it also produces and sells super-glue. But not the type you might use to fix broken crockery.

Instead it is the sort of adhesive that instantly knits cuts back together and is marketed as LiquiBand.

But lets back up a little and find out exactly what AMS does.

Its in the market for advanced wound-care so not the bog-standard bandages and plasters you might find in the first aid kit.

Mainly its products are used for chronic wounds, which might have become infected and require a special dressing.

Its range divides into two categories - foams and fibres - which are sold through a network of major suppliers.

However it also has a budget brand which it distributes through private label partners and markets direct to the NHS. Well hear more about this later.

AMS has a small bite of the advanced wound-care market, which is conservatively estimated to be worth US$3.6 billion and which is currently dominated by a handful of bigger players.

It means the group sits under the radar of industry giants such as Smith & Nephew, Systagenix and ConvaTec, which allows it to nibble away at the trios slice of the cake.

The intellectual property that makes its dressings stand out in the marketplace is protected by around 70 separate patents, while the group is able to refresh the offering thanks to a keen focus on research and development.

The recent interim results, meanwhile, show the group is expanding at quite a rate of knots.

Revenues advanced by 47 per cent year-on-year to 14.5 million in the six months to June 30, or 25 per cent if the contribution of Corpura, the recently acquired foams business, is excluded.

Pre-exceptional profits grew 136 per cent to 2.1 million, while AMS generated 1.4 million of cash in the period.

And unlike many of the small and growing firms in the healthcare sector it is even pledging to pay a dividend.

The plan is to hand over 10 per cent of post tax earnings initially and then progressively grow the payout after that.

We are still very much a capital growth stock, says Dr Don Evans, chief executive.

But we do believe paying a dividend is a good discipline.

We have a very good institutional, private client and retail investor base. And even the institutions think paying a dividend is a good thing. It shows we have grown up.

Investec predicts pre-tax profits this year will hit 5.1 million this year and advance to 6.3 million in 2011.

Over the past five years it has built a 20 per cent market share in silver products, sold through Systagenix and other partners, and AMS wants to build on this number two position.

We can continue to grow share, says Evans.

Meanwhile, the acquisition of the outstanding 50.6 per cent stake in Dutch company Corpura a year ago gives it a very strong position in the market for foam dressings and a platform on which to challenge the opposition. The integration has gone very well, Evans confirms.

He holds out high hopes for LiquiBand, the super-glue, whose launch in the US could transform the companys sales and earnings profile.

It is up against Dermabond, made by a J&J company, which accounts for 90 per cent of all glues sold.

Evans says the group will go in with a faster setting, slightly cheaper product.

The revenue split with partners Cardinal Healthcare and McKesson provides the sales staff and the respective companies with a very good incentive to promote LiquiBand to hospitals and doctors offices.

The hope is to build an around 20 per cent share of the 155 million-a-year glues market, establishing the same sort of base it has created for other products.

We have been beavering away in the UK and Europe with LiquiBand, Evans says. "But we clearly want to get into the US."

We have taken the past three years to work through the regulatory process, which has been quite tortuous. But we got there. And we are taking two products in the US market.

If we can do a good job with our products we can really penetrate the market.

Another growth channel is the budget range ActivHeal - which plays directly to cost-constrained healthcare providers such as NHS trusts.

The products do the job technically of their big branded equivalents, but offer a big saving typically 40 per cent, says Evans.

So we can go to an NHS trust and they are spending a certain amount of their budget on advanced wound care. So for routine wounds, straightforward wounds we can offer theme a range that does the job and saves them a chunk of money.

Then if it is a difficult wound, an infected wound they can then afford the higher value products.

That message is resonating very well at the moment because of the pressure on the NHS. The problem is theres not central decision-making so you have to do it trust by trust.

It is an incremental build. That business was up 20 per cent in the first half. But we are only in half the NHS trusts at the minute.

Recently the group has moved into one single facility at Winsford in the north west, which has the potential to treble the firms capacity giving a measure of Evans ambition.

The chief executive also believes he can deliver operational benefits from the new site that ought to drop to the bottom line. And with 24m off- balance sheet tax losses AMS is not expecting to pay tax for a few years yet.

The capital spending programme, the payment of a dividend and expenditure on R&D still leaves the company with enough cash to fund bolt-one acquisitions.

However, if Evans and his team want to do something more ambitious they will have to return to the market for additional funding, the chief executive admits.

We have got options. But we have enough to drive the organic business, he adds.

But we are mindful of the opportunities. We have a strong organic story, we dont need to do M& but it is the classic case that if we see something that is a good strategic fit and accelerates growth, we will do it.



AMS At a Glance

TICKER LON:AMS

Market Cap: 100 million

Sector: Healthcare (advanced wound-care)

Employs 240 people in Winsford, Plymouth and the Netherlands

Latest results: H1 2010 pre-tax profits of 2.1 million, up 136 per cent

juzzle
Good article 3 weeks old.
What caused todays rise after period of calm?????

Very good results and all looking good for the future (even a divi)

to the top

1st half figures due next week, recent news from company shows their intentions as to taking company forward. Be dissapointed if figures next week do not show continuing profits as per expectations at least

Stable - I'm sure you are aware , I posted this on the SUN thread yesterday.

RNS Number : 3798N

Advanced Medical Solutions Grp PLC

01 September 2011

For immediate release: 1 September 2011

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Development and Pre-Supply Agreement signed with Surgical Innovations Group plc

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has signed a Development and Pre-Supply Agreement ("the Agreement") with Surgical Innovations Group plc ("Surgical Innovations") (AIM: SUN), for the development and supply of a novel device for internal application of adhesives and sealants.

Under the terms of the Agreement, Surgical Innovations will develop and retain the intellectual property rights for a unique applicator to deliver accurately, individual drops of adhesive or sealant internally within the body, accessed via a minimally invasive surgical port site. In return for the exclusive rights to this applicator for the internal application of adhesives and sealants, AMS has agreed to purchase all of its requirements for the approved new applicator from Surgical Innovations for a period of ten years.

The development of the internal applicator is a key step in extending the Company's expertise in adhesives and sealants from purely topical applications to also addressing clinical needs inside the body. AMS has previously highlighted that the first target internal application would be the hernia mesh fixation market which is currently served by sutures, staples and tacks. This new internal applicator, together with the Company's adhesives, will allow AMS to address this important market with reduced surgical complications.

Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS said:

"This agreement combines our formulation and regulatory expertise with Surgical Innovations' applicator design and manufacturing expertise to introduce a new product to a global market for internal sealants that is now in excess of US$600 million. As we have previously indicated, an integral part of our tissue sealant and adhesives R&D is focused on moving our product range more towards the Operating Room, including internal applications. In this regard, we are optimistic that our partnership with Surgical Innovations will give us a market leading product, targeting the hernia mesh fixation market, which should be available for launch in 2013."

Graham Bowland, Chief Executive Office of Surgical Innovations added:

"Our agreement with AMS affirms SI's reputation in delivering leading design solutions to OEM customers. The applicator device for AMS is a natural extension to our existing minimally invasive surgical product portfolio and we have already commenced on the design work on a fully disposable device. As part of the agreement SI will retain the full intellectual property rights to the applicator device and will also manufacture it on behalf of AMS."

skinny
Thks, I had already seen it. I think this continues to show that Ams have the mind set to develop the company as it surely leads in time for a take over.

Half Yearly Report.

Business Highlights:

LiquiBand achieves 5% volume share in the US in only its second year of sales

Sales of ActivHeal into the NHS up 64% compared to the same period last year

Foam strategy delivering strong growth of 25% on the first half of 2010

Silver alginate growth continues to outstrip the wider market

New facility already delivering operational efficiencies and margin improvements

Financial Highlights:

Group revenue up 12% to 16.3 million (2010 H1: 14.5 million)

at constant currency1 revenue increased 14%

Profit from operations (pre-exceptional items2) up 25% to 2.6 million (2010 H1: 2.1 million)

profit from operations (post exceptional items2) up 80% to 2.6 million (2010 H1: 1.5 million)

Operating margin (pre-exceptional items2) up 160 basis points to 16.1% (2010 H1: 14.5%)

operating margin (post-exceptional items2) up 610 basis points to 16.1% (2010 H1: 10.0%)
Basic earnings per share (pre-exceptional items2) up 21% to 1.72p (2010 H1: 1.42p)

basic earnings per share (post exceptional items2) up 74% to 1.72p (2010 H1: 0.99p)

Net funds3 after payment of maiden dividend were 3.6 million (2010 H1: net debt 0.3 million)

Interim dividend of 0.145p per share to be paid

RNS Number : 2417T

Advanced Medical Solutions Grp PLC

02 December 2011

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN) IS restricted and is NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL

Strictly Embargoed until 07.00 2 December 2011

Advanced Medical Solutions Group plc ("AMS", the "Company" or the "Group")

Placing of 47,236,112 new Ordinary Shares in AMS at a price of 72 pence per share to raise approximately GBP34.0 million in connection with the proposed acquisition of RESORBA Wundversorgung GmbH & co. KG

The Board of AMS (AIM: AMS), the global medical technology company, is pleased to announce today the proposed acquisition of RESORBA, a long established wound care and wound closure business headquartered in Germany for a total cash consideration of EUR63.8 million (approximately GBP55 million) on a debt-free, cash-free basis to be paid, in full, on completion. To fund the acquisition, the Board of AMS also announces today a non pre-emptive institutional placing (the "Placing") of 47,236,112 new Ordinary Shares in AMS (the "Placing Shares") at a price of 72 pence per Placing Share (the "Placing Price"), to raise approximately GBP34.0 million (GBP30.5 million net of acquisition and placing expenses), together with a EUR25.0 million term loan facility.


-- The acquisition of RESORBA fulfils all of AMS's strategic
acquisition criteria and provides a number of commercial
synergy opportunities as it:
-- Broadens the Group's technology portfolio in both wound
care and wound closure;
-- Provides direct sales capability into the operating
room in Germany, Czech Republic and Russia;
-- Provides significant cross-selling opportunities and
product development potential;
-- Provides access to a new market - oral surgery;
-- Leverages AMS's global distribution network and regulatory
expertise to bring existing RESORBA products to new
markets; and
-- Provides development opportunities in the short, medium
and long term
-- RESORBA is well known to AMS as it currently distributes
its LiquiBand(R) wound closure product and has done for
more than eight years
-- Acquisition is expected to be earnings per share enhancing
in the twelve months ending 31 December 2012(1)
-- Senior management of RESORBA will be joining the Enlarged
Group and investing a material proportion of their net
proceeds from the Acquisition in AMS shares
-- Significant shareholder support for the Placing

(1) This statement is not intended, nor is to be construed as a profit forecast or to be interpreted to mean that earnings per AMS Share for the current or future financial years, or those of the Enlarged Group, will necessarily match or exceed the historical earnings per AMS Share.

Commenting on the Acquisition, Chris Meredith, Chief Executive Officer of AMS said:

"Part of our core growth strategy has been to examine potential acquisition opportunities that strengthen our business with complementary technologies and greater market access, specifically in relation to the operating room segment of our global business. It is rare to find a business that fits our criteria as well as RESORBA does. We have known RESORBA for a number of years as a result of our LiquiBand(R) relationship, and I am confident that the enlarged AMS Group will benefit from a wide range of commercial opportunities that will enable us to continue the strong progress made in recent years."

The Placing is conditional, inter alia, on Shareholder approval of the Special Resolution at the General Meeting. It is expected that the Company will post a Circular to all AMS Shareholders today with details of the Placing, Acquisition, the New Debt Facility and giving notice of the General Meeting, to be held at 11.00 a.m. on 19 December 2011 at the offices of Investec Bank plc, 2 Gresham Street, London EC2V 7QP. A copy of this Announcement and the Circular will be available on the Company's website, www.admedsol.com.

A bit more volume would be nice.

skinny
I think anything over 1 mill is big for ams, recent vloume on downside was one reason for not getting worried as it was very low.
It will be interesting in the middle of this month if they give an update prior to end of year, where will end 2011?

Yes I guess that comparatively speaking, the volume is well above average - I can't lay my hands on it atm, but I've had a sell note on this in the last week - more excellent coverage! :-)

Skinny
re yesterdays trading, I wonder what was the reason for the afternoon volume, either good lunches in london, or was it U.S. buying interest.I do not want a takeover in the near future as I feel all is in place for another 100 pc rise within 24 months, but, I cannot believe a large US company is not watching and knowing the short sighted Uk financial wonders they will take a nice profit if forthcoming,

re your sale note, I saw one about 10 days ago that forecast value at70p and then share magasine talked also about 70p, I wonder what they are saying this week

Now there's a bit more volume.

Standard Life < 8%

Octopus Investments > 4%

Skinny
Now u have your volume, looks like house broker has taken up the offering.
Standard dropping 500k may well be taking a profit on recent 72p purchase. They last bought at 95p,. I did read/hear somewhere that they have a limit on the amount that they will hold in any one company. Notice Octopus purchase dated last Friday so that cannot be the 72 placing as that is not yet confirmed until after the vote